Every material Form 8-K Protagonist Therapeutics filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Protagonist Therapeutics reported third quarter 2026 financial results, highlighted by net income of $220.0 million and license and collaboration revenue of $274.4 million, driven by partner payments following FDA approval of MIMRYLO. Cash, cash equivalents, and marketable securities reached $834.6 million as of September 30, 2026. The company also announced a $300 million share repurchase program authorized in September 2026.
Net income for the third quarter of 2026 was $220.0 million, or $3.07 per diluted share, compared to a net loss of $39.3 million, or $0.62 per diluted share, for the third quarter of 2025.
License and collaboration revenue reached $274.4 million for the third quarter of 2026, primarily driven by $266.6 million in proportional recognition from Takeda following the FDA approval of MIMRYLO.
Cash, cash equivalents, and marketable securities totaled $834.6 million as of September 30, 2026.
The Board of Directors authorized a $300 million share repurchase program announced on September 8, 2026.
Protagonist Therapeutics reported net income of $162.8 million for the quarter ended June 30, 2026, compared with a net loss of $34.8 million a year earlier. Most of the quarter's $213.5 million in license and collaboration revenue came from $192.4 million recognized from the Takeda opt-out payment, so the result reflects a large one-time-style accounting benefit rather than the ongoing run rate. The company also said it expects research and development expense to rise significantly in the second half of 2026.
Q2 2026 license and collaboration revenue was $213.5 million, versus $5.5 million in Q2 2025; $192.4 million relates to the Takeda opt-out payment.
Q2 2026 net income was $162.8 million, or $2.29 per diluted share, versus a net loss of $34.8 million, or $0.55 per share, a year earlier.
R&D expense was $42.1 million in Q2 2026, up from $37.0 million, and the company expects R&D expense to increase significantly in the second half of 2026.
Cash, cash equivalents and marketable securities were $849.5 million at June 30, 2026, up from $646.0 million at December 31, 2025; rusfertide has an FDA PDUFA goal date in August 2026.
At its annual meeting, Protagonist Therapeutics stockholders approved the company's 2026 Equity Incentive Plan, which replaces the 2016 plan and adds 650,000 new shares for future awards. Stockholders also re-elected two Class I directors and approved the other proposals, including a non-binding say-on-pay vote and the ratification of Ernst & Young LLP as auditor.
2026 Equity Incentive Plan approved, adding 650,000 new shares plus returned shares from the 2016 plan
Dinesh V. Patel, Ph.D., received 48,714,702 votes for and Lewis T. "Rusty" Williams, M.D., Ph.D., received 45,371,193 votes for
Non-binding say-on-pay proposal approved with 53,412,559 votes for and 3,164,702 against
Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026
Protagonist reported first-quarter 2026 results, with net income of $3.8 million ($0.05 per diluted share) compared with a net loss of $11.7 million ($0.19 per share) a year earlier. Revenue rose to $56.4 million from $28.3 million, mainly due to a $50.0 million milestone from Johnson & Johnson after the FDA approved ICOTYDE, so shareholders should note that the profit depends heavily on this one-time payment while R&D spending also increased.
Net income of $3.8 million, or $0.05 per diluted share, versus a net loss of $11.7 million, or $0.19 per share, in Q1 2025
License and collaboration revenue of $56.4 million, including a $50.0 million milestone from Johnson & Johnson tied to FDA approval of ICOTYDE in March 2026
R&D expense rose to $46.7 million from $35.9 million, driven mainly by the PN-881 Phase 1 study and discovery research
Cash, cash equivalents and marketable securities were $620.3 million at March 31, 2026, down from $646.0 million at December 31, 2025
Protagonist reported fourth-quarter 2025 license and collaboration revenue of $7.4 million, down from $170.6 million a year earlier, and a net loss of $44.4 million, or $0.69 per share, compared with net income of $131.7 million in the prior-year quarter. For the full year, revenue fell to $46.0 million and the net loss was $130.1 million, and the company said the decline reflects lower, highly variable milestone revenue.
Q4 2025 license and collaboration revenue was $7.4 million, versus $170.6 million in Q4 2024, a decrease of $163.2 million.
Q4 2025 net loss was $44.4 million, or $0.69 per share, versus net income of $131.7 million, or $2.11 per basic share, a year earlier.
Full-year 2025 net loss was $130.1 million, or $2.05 per share, compared with net income of $275.2 million in 2024.
Cash, cash equivalents and marketable securities were $646.0 million at December 31, 2025, which the company expects to fund operations through at least the end of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Protagonist Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →